BRAF and neoplasm: In line with this hypothesis, Wang et al. [10] demonstrated that loss of SMARCB1 (INI-1) expression occurs at least focally in 0.46% of 3051 CRCs and is associated with higher grade, larger tumor size, poorer survival, MSI, and BRAF V600E mutation.